News & Events 2026
19 May 2026
Agafi (Aflibercept) Launch Program – 19th May 2026, Intercontinental Dhaka Incepta
Pharmaceuticals proudly hosted the launch of Agafi (Aflibercept) on 19th May 2026 at the Intercontinental Dhaka, marking a significant milestone in advanced retinal care in Bangladesh. The event brought together leading retina specialists and ophthalmologists from across the country to discuss innovative solutions for retinal vascular diseases, including Diabetic Macular Edema (DME), Wet AMD, Retinal Vein Occlusion (RVO), and more.
The program featured keynote presentations by eminent experts highlighting the role of biosimilars in ophthalmology and the clinical benefits of Aflibercept in preserving vision and reducing treatment burden. The interactive panel discussion allowed the attending specialists to share insights, clinical experiences, and practical approaches in patient management, fostering knowledge exchange on the latest advancements in retinal care.
With the launch of Agafi, Incepta Pharmaceuticals reinforces its commitment to making high-quality, affordable, and locally manufactured biosimilar therapies accessible to patients in Bangladesh, helping improve outcomes and broaden access to life-saving retinal treatments.
15 January 2026
We are proud to announce the first-ever launch of Semaglutide injections in Myanmar under the brand name ORSEMA – a breakthrough therapy for diabetes and weight management that is transforming global healthcare standards.
This milestone reflects Incepta’s commitment to innovation and patient care, ensuring that advanced treatment options reach those who need them most. Bringing ORSEMA to Myanmar ahead of time was possible thanks to dedication, collaboration, and strategic partnerships.
A special note of appreciation to ABC International ,Myanmar and all stakeholders who contributed to making this vision a reality. Your support and hard work have set a new benchmark for excellence.
